Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase NA 1

Status

Unknown 3Completed 1

Sponsor Class

OTHER 4NIH 2NETWORK 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Thoracic 2Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Leukemia 3Recurrence 2Myeloproliferative Disorders 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Hairy Cell 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 678Cytarabine 576fludarabine 410fludarabine phosphate 387venetoclax 310Methotrexate 297Rituximab 283Azacitidine 264Busulfan 248Whole-Body Irradiation 220Etoposide 215Filgrastim 214Peripheral Blood Stem Cell Transplantation 211Mycophenolic Acid 206Tacrolimus 196Dexamethasone 191Granulocyte Colony-Stimulating Factor 182Vincristine 173Melphalan 173Decitabine 163Cyclosporine 146Daunorubicin 139Antilymphocyte Serum 137Idarubicin 134Imatinib Mesylate 127Lenalidomide 116Doxorubicin 109Radiotherapy 108Stem Cell Transplantation 107Clofarabine 106

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Biological Therapy × Other hematologic neoplasm × Clear all
NCT01872819 2018-07-11

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

University of Washington

Phase NA Completed
16 enrolled 9 charts
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute

NCT00515892 2007-08-14

NHL

Cambridge Antibody Technology

Phase 1 Unknown
50 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Non-Hodgkin

NCT00462189 2007-04-18

Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease

Cambridge Antibody Technology

Phase 1 Unknown
40 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Recurrence

NCT00457860 2007-04-17

Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease

Cambridge Antibody Technology

Phase 1 Unknown
50 enrolled
Other hematologic neoplasm

Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡